Researchers in protective gear examining samples in a state-of-the-art laboratory setting.

Huntington’s disease research: what October taught us

October offered plenty of promising news and innovative approaches in Huntington’s disease research around the world. This month, we learned about results from the latest phase of an experimental RNA therapy, millions awarded for new HD research, and more promising gene-editing techniques on the horizon.

Read on for a recap of Huntington’s disease news from October.

Initial results from RNA interference therapy trial

At the 2026 European Huntington’s Disease Network (EHDN) Clinical Research Congress in Poland, last week, biopharmaceutical company Alnylam presented results from Phase 1b of its clinical trials for ALN-HTT02. The experimental RNA interference (RNAi) therapy, to be developed under the name brezosiran, is designed to reduce all forms of the huntingtin (HTT) protein by targeting the HTT messenger RNA.

During the initial Phase, 48 participants with Huntington’s disease received the treatment by injection. Early results from Phase 1b showed reductions in the altered HTT protein and were well tolerated by participants.

In the next Phase, researchers will continue with long-term follow-up to assess safety and efficacy, with participants receiving brezosiran every six months for up to three years. Additionally, Alnylam plans to launch a larger placebo-controlled trial in 2027 to determine whether reducing HTT protein can slow disease progression.

Although there is no news yet about expanding the trial to include Australia, we will share any updates. Learn more about how RNAi therapy works here.

Gene-editing enzyme targets CAG repeats

Researchers at Cardiff University have developed a modified CRISPR gene-editing technique that shortened the expanded DNA repeat sequences responsible for Huntington’s disease in mice. After initial trials, researchers reported reduced toxic protein build-up, healthier gene activity in brain cells, and significant improvements in movement in treated mice.

This unique approach uses a special gene-editing enzyme (Cas9 nickase) to cut just one DNA strand. If successful, it could offer a safer way to target the HD-causing CAG repeats.

Although initial results are promising in animal studies, it is still at the preclinical stage. Researchers will continue to conduct further studies to confirm its safety, effectiveness and suitability for human trials.

$2 million awarded to Huntington’s research

Global Huntington’s disease research received a boost recently, as the Huntington’s Disease Foundation (HDF) awarded $2 million for its 2026 Transformative Research Awards (TRAs). The latest funding supports two research collaborations with different approaches to the same goal: targeting the protein associated with HD.

The 2026 recipients include a team led by Dr Rachel Harding of the Structural Genomics Consortium and the University of Toronto, focusing on a small molecule that binds to huntingtin. The other recipient is Dr Ai Yamamoto of Columbia University’s team, whose approach is on strengthening the brain’s cellular cleanup systems.

With each team awarded $1 million to pursue these strategies, HDF continues to support future treatments for Huntington’s disease.

A month of new avenues for research

October provided many opportunities to learn about new research and innovative techniques, leaving us more hopeful than ever. We look forward to learning more as 2026 comes to a close, and everything researchers will discover in the new year.

We will keep you updated on news around Huntington’s disease, particularly as it affects our Australian community. Check in with the Huntington’s Australia’s news page and our social media for the latest.

Share this article

Similar Posts

View all news